Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Equillium Inc (EQ)

Equillium Inc (EQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,357
  • Shares Outstanding, K 35,255
  • Annual Sales, $ 36,080 K
  • Annual Income, $ -13,340 K
  • 60-Month Beta 1.77
  • Price/Sales 1.37
  • Price/Cash Flow N/A
  • Price/Book 2.34
Trade EQ with:

Options Overview Details

View History
  • Implied Volatility 91.64% ( -30.74%)
  • Historical Volatility 78.75%
  • IV Percentile 12%
  • IV Rank 3.88%
  • IV High 1,085.67% on 07/25/23
  • IV Low 51.51% on 05/22/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 11
  • Volume Avg (30-Day) 17
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,567
  • Open Int (30-Day) 1,507

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.15
  • Number of Estimates 3
  • High Estimate -0.08
  • Low Estimate -0.22
  • Prior Year -0.10
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3200 +6.06%
on 05/01/24
1.8900 -25.93%
on 05/10/24
-0.3900 (-21.79%)
since 04/24/24
3-Month
1.3200 +6.06%
on 05/01/24
3.2500 -56.92%
on 02/26/24
-1.1400 (-44.88%)
since 02/23/24
52-Week
0.4500 +211.11%
on 11/13/23
3.2500 -56.92%
on 02/26/24
+0.7499 (+115.35%)
since 05/24/23

Most Recent Stories

More News
Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders...

EQ : 1.4000 (unch)
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders...

EQ : 1.4000 (unch)
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced...

EQ : 1.4000 (unch)
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an oral presentation...

EQ : 1.4000 (unch)
Equillium to Present at the SVB Securities Annual Global Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced...

EQ : 1.4000 (unch)
Equillium Announces Abstract Accepted for Oral Presentation at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an abstract was...

EQ : 1.4000 (unch)
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement

Equillium, Inc. (Nasdaq: EQ) and Metacrine, Inc. today announced the mutual termination of their previously announced definitive merger agreement.

EQ : 1.4000 (unch)
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Biocon Limited,...

EQ : 1.4000 (unch)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MVBF, EQ, MTCR, SESN

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

MVBF : 18.22 (-0.55%)
EQ : 1.4000 (unch)
MTCR : 0.5814 (-1.29%)
SESN : 12.5760 (+7.29%)
SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

EQ : 1.4000 (unch)
IMGO : 36.01 (+0.03%)
MTCR : 0.5814 (-1.29%)
OPNT : 20.65 (-0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 1.5818
2nd Resistance Point 1.5335
1st Resistance Point 1.4667
Last Price 1.4000
1st Support Level 1.3516
2nd Support Level 1.3033
3rd Support Level 1.2365

See More

52-Week High 3.2500
Fibonacci 61.8% 2.1804
Fibonacci 50% 1.8500
Fibonacci 38.2% 1.5196
Last Price 1.4000
52-Week Low 0.4500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar